About Horizon Therapeutics
Horizon Therapeutics is a company based in Dublin (Ireland) founded in 2008 was acquired by Amgen in December 2022. Horizon Therapeutics has raised $61.78 million across 7 funding rounds from investors including Amgen. Horizon Therapeutics has completed 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma. Horizon Therapeutics offers products and services including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model. Horizon Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Forge Biologics, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amgen Inc.
-
Annual Revenue
$617.41 M (USD)14as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$61.78 M (USD)
in 7 rounds
-
Latest Funding Round
$69.4 M (USD), Post-IPO
Oct 01, 2014
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Crealta Pharmaceuticals
& 4 more
-
Acquired by
Amgen
(Dec 12, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Horizon Therapeutics
Horizon Therapeutics offers a comprehensive portfolio of products and services, including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model.
Treatments for serious diseases using biologic agents
Platform for screening compounds in drug design
Machine learning for accelerating clinical trials
People of Horizon Therapeutics
Unlock access to complete
Unlock access to complete
Software Development Team
208 people
Leadership Team
193 people
Sales and Marketing
82 people
Data Analysis and Operations Team
73 people
Senior Team
66 people
Operations Team
64 people
Product Management Team
55 people
Scientific Team
34 people
Unlock access to complete
Funding Insights of Horizon Therapeutics
Horizon Therapeutics has successfully raised a total of $61.78M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $69.4 million completed in October 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Horizon Therapeutics
Horizon Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceutical products for treating multiple diseases
|
Locked | Locked | Locked |
Investor details for Horizon Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Horizon Therapeutics
Horizon Therapeutics has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma.
Investment portfolio details for Horizon Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of biologics for treating severe inflammation and autoimmune diseases
|
Locked | Locked | 2017 | Locked | |
|
Biologic medicines are developed and manufactured for serious illnesses.
|
Locked | Locked | 2013 | Locked | |
|
Developer of protein based therapeutics for the treatment of chronic granulomatous disease and malignant osteopetrosis
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Horizon Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Horizon Therapeutics
Detailed financials for Horizon Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Horizon Therapeutics Comparisons
Peer comparison for Horizon Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Horizon Therapeutics
Horizon Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Forge Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Horizon Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Horizon Therapeutics
Complete news archive for Horizon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Horizon Therapeutics
Horizon Therapeutics was founded in 2008.
Horizon Therapeutics is headquartered in Dublin, Ireland.
Timothy Walbert is the current CEO of Horizon Therapeutics.
Horizon Therapeutics is a funded company, having raised a total of $61.78M across 7 funding rounds to date.
Annual revenue of Horizon Therapeutics is $617.41M as on Dec 31, 2022.
Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogrens syndrome.
Horizon Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Horizon Therapeutics offers Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model.
Horizon Therapeutics has made 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma, and Raptor Pharma.
Horizon Therapeutics has 1 investor. Key investors include Amgen.